Dr. Kreher has decades of expertise in rare disease drug development, including extensive experience in clinical development, medical affairs, and regulatory strategy across both early- and late-stage programs. She is an accomplished physician executive and pediatric endocrinologist with a distinguished career in biotechnology, spanning leadership roles in both private and public biotech companies. Nerissa has been instrumental in the development and commercialization of therapies for rare diseases across therapeutic areas, including neuromuscular, metabolic, and lysosomal storage disorders.

Prior to Alltrna, Nerissa served as CMO at Entrada Therapeutics, where she led clinical and regulatory strategy, medical affairs, and patient advocacy efforts. She has also held CMO roles at Tiburio Therapeutics and AVROBIO, where she oversaw clinical development for multiple gene therapy programs. Earlier in her career, she served as Global Head (VP) of Clinical and Medical Affairs at Zafgen and held key roles at Shire and Enobia Pharma. She also played a pivotal role in Alexion’s $1B+ acquisition of Enobia Pharma. Dr. Kreher currently serves as an independent board member of Rezolute Bio.

Please join us for this exciting session to learn how Dr. Kreher and the Alltrna team are working to revolutionize treatment options for patients living with Stop Codon Diseases.